Russell K. Portenoy, M.D., Medical Advisor: Dr. Russell Portenoy is Chairman and the Gerald J. and Dorothy R. Friedman Chair in Pain Medicine and Palliative Care of the Department of Pain Medicine and Palliative Care at the Beth Israel Medical Center in New York, and Professor of Neurology and Anesthesiology at the Albert Einstein College of Medicine. He is an immediate past-President of the American Academy of Hospice and Palliative Medicine and a past President of the American Pain Society. He is the recipient of the Wilbert Fordyce Award for Lifetime Excellence in Clinical Investigation, the Distinguished Service Award from the American Pain Society, the Founder's Award from the American Academy of Pain Medicine, and the Bonica Award from the Eastern Pain Association. He serves on the Board of Directors of the American Pain Foundation and chairs both the medical forum of the National Hospice Work Group and the Committee on Hospice and Palliative Medicine of the Accreditation Council for Graduate Medical Education. Dr. Portenoy's research has focused on clinical trials of analgesic drugs, opioid pharmacology, symptom measurement, and quality of life assessment. He is editor-in-chief of the Journal of Pain and Symptom Management.
Robert F. Kaiko, Ph.D., Dr. Kaiko recently joined Cytogel Pharma Advisory Board as a scientific and clinical consultant, advising the Company on the development of its novel endomorphin compound, Cyt-1010.
Dr. Kaiko began his career in the industry when he joined The Purdue Frederick Company in 1985 as associate medical director. He has held a number of positions of increasing responsibility, including vice president of clinical research and vice president, R&D portfolio development. He retired from Purdue Pharma in 2013. While at Purdue he contributed to the clinical development of controlled-release oral morphine (MS Contin), led the development of controlled-release oral oxycodone (OxyContin) and its recent reformulation, and initiated the clinical development of transdermal buprenorphine (BuTrans) and other analgesics.
Pain treatment, specifically, opioid analgesia, has been a focus during his career, and Dr. Kaiko is an inventor on a number of patents in this area. He has published 100 peer reviewed articles and almost 200 abstracts.
Dr. Kaiko served as a board member for Pain and Analgesia and PRN Forum and was a contributing editor for the Journal of Pain and Symptom Management and Cancer Pain Release. He was a reviewer for the Journal of Pharmaceutical Sciences and several other research publications. He has also served as president and board member of the Eastern Pain Association.
Dr. Kaiko has consulted for the Food and Drug Administration, the Drug Abuse Advisory Board, the Federal Trade Commission, and the World Health Organization. He was also a grant reviewer and site visitor for the National Cancer Institute and the Veteran's Administration.
awarded the Pharmacology Prize from the School. He obtained his Ph.D. in pharmacology in 1974 from Cornell University Graduate School of Biomedical Sciences in New York City. He then became a research associate at Sloan-Kettering Institute for Cancer Research in the Analgesic Studies Section. Dr. Kaiko was also a postdoctoral research fellow, instructor and adjunct assistant professor at Cornell University Graduate School of Biomedical Sciences in the Department of Pharmacology.
Bob A. Rappaport, M.D., Dr. Rappaport joined the Cytogel Advisory Board as a Consultant in 2015, having retired from the FDA in October of 2014. Dr. Rappaport was Director of the Division of Anesthesia, Analgesia, and Addiction Products at the FDA for 12 years where he led a large team of physicians, scientists and regulatory project managers to oversee the investigation, development, approval, continued safety, and safe use of drug products to treat pain and addiction disorders, as well as drug products used in the setting of clinical anesthesia. He was an advocate for the development of novel analgesic, anesthetic and addiction drug products throughout his tenure, and instituted new standards for the study of these drugs. He has also been an active member of the IMMPACT consensus group since its inception. In 2010 he worked within FDA to build the ACTTION (Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks) public-private-partnership, which was initially designed to advance the field of analgesic drug development by improving analgesic clinical study design, conduct and analysis. This highly successful initiative was later expanded to include improving the study and development of anesthetics, and drugs to treat addiction and peripheral neuropathy. Dr. Rappaport was centrally involved with the FDA's continued efforts to encourage and assist in the development of abuse-deterrent opioid formulations, and with his staff he completed an updated guidance for the pharmaceutical industry on the development of analgesic drug products. In 2013, Dr. Rappaport received the Agency's Lifetime Achievement Award for his contributions to the anesthesia, analgesia, and addiction fields by accelerating the discovery and development of new drugs with improved efficacy and safety.
Dr. Rappaport graduated from and completed his medical training at The George Washington University School of Medicine and Health Sciences, and is board certified in neurology and sleep medicine. In May of this year Dr. Rappaport will receive the 2015 John and Emma Bonica Public Service Award at the annual meeting of the American Pain Society. The Bonica Award recognizes distinguished contributions to the field of pain through public education, dissemination of information, public service, or other efforts that further knowledge about pain.